RecruitingNCT04290806
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy
Sponsor
iOMEDICO AG
Enrollment
1,900 participants
Start Date
Dec 4, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
Eligibility
Min Age: 18 Years
Inclusion Criteria6
- Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC
- Planned palliative systemic first-line therapy
- Age \>= 18 years
- Signed informed consent (IC)
- Patients answering questionnaires: IC before first therapy cycle
- Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle
Exclusion Criteria1
- No systemic therapy for ESCC, EAC, GAC or GEJAC
Interventions
OTHERRoutine care as per site standard
Physician's choice according to patient's needs. Routine care as per site standard.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04290806
Related Trials
Obeticholic Acid for Prevention in Barrett's Esophagus
NCT049390518 locations
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT074546422 locations
Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC
NCT074031361 location
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892139 locations
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632154 locations